Pioglitazon (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pioglitazon" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

11nih.gov

4^th place

13^th place

9doi.org

2^nd place

4^th place

5web.archive.org

1^st place

3fda.gov

447^th place

792^nd place

2books.google.com

3^rd place

6^th place

2clincalc.com

3,912^th place

low place

1drugs.com

399^th place

480^th place

1medicaid.gov

low place

1ulg.ac.be

7,875^th place

low place

1archive.org

6^th place

2^nd place

1lefigaro.fr

113^th place

3,083^rd place

1medical-reference.net

low place

1reuters.com

49^th place

96^th place

1harvard.edu

18^th place

44^th place

1drugpatentwatch.com

low place

archive.org

Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (edisi ke-8th). Foster City, CA: Biomedical Publications. hlm. 1271–1272.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. hlm. 450. ISBN 9783527607495.
Burant C (2012). Medical Management of Type 2 Diabetes. American Diabetes Association. hlm. 63. ISBN 9781580404570.

clincalc.com

"The Top 300 of 2020". ClinCalc. Diakses tanggal 11 April 2020.
"Pioglitazone - Drug Usage Statistics". ClinCalc. Diakses tanggal 11 April 2020.

doi.org

Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. PMID 23020930. Diarsipkan dari versi asli tanggal 2021-01-28. Diakses tanggal 2020-05-23. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (September 2007). "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials". JAMA. 298 (10): 1180–8. doi:10.1001/jama.298.10.1180. PMID 17848652.
Filipova E, Uzunova K, Kalinov K, Vekov T (August 2017). "Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis". Diabetes Therapy. 8 (4): 705–726. doi:10.1007/s13300-017-0273-4. PMC 5544610 . PMID 28623552.
Gillies PS, Dunn CJ (August 2000). "Pioglitazone". Drugs. 60 (2): 333–43; discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737.
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702.
Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346 . PMID 17766440.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E (2017). "Pioglitazone could induce remission in major depression: a meta-analysis". Neuropsychiatric Disease and Treatment. 13: 9–16. doi:10.2147/NDT.S121149. PMC 5182046 . PMID 28031713.
Doyle CA, McDougle CJ (August 2012). "Pharmacotherapy to control behavioral symptoms in children with autism". Expert Opinion on Pharmacotherapy. 13 (11): 1615–29. doi:10.1517/14656566.2012.674110. PMID 22550944.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010). "Lipid disturbances in psoriasis: an update". Mediators of Inflammation. 2010: 535612. doi:10.1155/2010/535612. PMC 2914266 . PMID 20706605.

drugpatentwatch.com

"Details for Actos". Drug Patent Watch.

drugs.com

"Pioglitazone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Diakses tanggal 3 March 2019.

fda.gov

Takeda (March 2007). "Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOSO (pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus" (PDF). Diarsipkan dari versi asli (PDF) tanggal 2012-05-16. Diakses tanggal 2012-04-04.
"FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines". United States Food and Drug Administration. 4 August 2011.
"FDA approves first generic Actos to treat type 2 diabetes". United States Food and Drug Administration. 17 August 2012. Diarsipkan dari versi asli tanggal 4 January 2016.

harvard.edu

adsabs.harvard.edu

Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346 . PMID 17766440.

lefigaro.fr

"L'antidiabétique Actos retiré du marché" [Actos antidiabetic withdrawn from the market]. Le Figaro (dalam bahasa French). 9 June 2011.

medicaid.gov

data.medicaid.gov

"NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2019-03-06. Diakses tanggal 3 March 2019.

medical-reference.net

Alam, Imtiaz Ibne (1 January 2012). "France and Germany Suspended Use of Actos for Bladder Cancer Risk". Medical-Reference.

nih.gov

ncbi.nlm.nih.gov

Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. PMID 23020930. Diarsipkan dari versi asli tanggal 2021-01-28. Diakses tanggal 2020-05-23. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (September 2007). "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials". JAMA. 298 (10): 1180–8. doi:10.1001/jama.298.10.1180. PMID 17848652.
Filipova E, Uzunova K, Kalinov K, Vekov T (August 2017). "Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis". Diabetes Therapy. 8 (4): 705–726. doi:10.1007/s13300-017-0273-4. PMC 5544610 . PMID 28623552.
Gillies PS, Dunn CJ (August 2000). "Pioglitazone". Drugs. 60 (2): 333–43; discussion 344–5. doi:10.2165/00003495-200060020-00009. PMID 10983737.
Smith U (September 2001). "Pioglitazone: mechanism of action". International Journal of Clinical Practice. Supplement (121): 13–8. PMID 11594239.
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR (February 2004). "Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe". American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252–60. doi:10.1152/ajpendo.00424.2003. PMID 14570702.
Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN, Nechushtai R, Dixon JE, Jennings PA (September 2007). "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone". Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342–7. Bibcode:2007PNAS..10414342P. doi:10.1073/pnas.0707189104. PMC 1963346 . PMID 17766440.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E (2017). "Pioglitazone could induce remission in major depression: a meta-analysis". Neuropsychiatric Disease and Treatment. 13: 9–16. doi:10.2147/NDT.S121149. PMC 5182046 . PMID 28031713.
Doyle CA, McDougle CJ (August 2012). "Pharmacotherapy to control behavioral symptoms in children with autism". Expert Opinion on Pharmacotherapy. 13 (11): 1615–29. doi:10.1517/14656566.2012.674110. PMID 22550944.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010). "Lipid disturbances in psoriasis: an update". Mediators of Inflammation. 2010: 535612. doi:10.1155/2010/535612. PMC 2914266 . PMID 20706605.

dailymed.nlm.nih.gov

"Actos- pioglitazone tablet". DailyMed. 25 January 2019. Diakses tanggal 13 February 2020.

reuters.com

Topham, James (June 10, 2011). "UPDATE 2-Germany joins France in suspending top Takeda drug". Reuters. Diarsipkan dari versi asli tanggal 2015-11-13. Diakses tanggal 2020-05-23.

ulg.ac.be

orbi.ulg.ac.be

Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. PMID 23020930. Diarsipkan dari versi asli tanggal 2021-01-28. Diakses tanggal 2020-05-23. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.

web.archive.org

"NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (dalam bahasa Inggris). Diarsipkan dari versi asli tanggal 2019-03-06. Diakses tanggal 3 March 2019.
Scheen AJ (November 2012). "Outcomes and lessons from the PROactive study". Diabetes Research and Clinical Practice. 98 (2): 175–86. doi:10.1016/j.diabres.2012.09.001. PMID 23020930. Diarsipkan dari versi asli tanggal 2021-01-28. Diakses tanggal 2020-05-23. Since 2005, there has been much debate on the relative value of the statistically non-significant 10% reduction in the quite challenging primary composite endpoint (combining cardiovascular disease-driven and procedural events in all vascular beds) versus the statistically significant 16% decrease in the more robust and conventional main secondary endpoint (all-cause mortality, myocardial infarction, and stroke) observed with pioglitazone.
Takeda (March 2007). "Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with ACTOSO (pioglitazone HOI) Tablets for Type 2 Diabetes Mellitus" (PDF). Diarsipkan dari versi asli (PDF) tanggal 2012-05-16. Diakses tanggal 2012-04-04.
Topham, James (June 10, 2011). "UPDATE 2-Germany joins France in suspending top Takeda drug". Reuters. Diarsipkan dari versi asli tanggal 2015-11-13. Diakses tanggal 2020-05-23.
"FDA approves first generic Actos to treat type 2 diabetes". United States Food and Drug Administration. 17 August 2012. Diarsipkan dari versi asli tanggal 4 January 2016.